DXCM reports Q1 revenue growth

What happened: On April 30, 2023, DexCom (DXCM) reported Q1 2023 revenue of $1.192 billion, up 15% year-over-year, driven by an 11% rise in US revenue and a 26% jump internationally. Following this, DXCM stock surged 6.6% on May 5, 2023, bolstered by its upbeat full-year outlook. At its investor day, DexCom outlined a long-term growth plan targeting over 10% annual revenue growth through 2030, along with margin expansion and a $1 billion share repurchase program.

Market impact: The medical device sector, particularly continuous glucose monitoring (CGM) companies, is affected. DexCom's strong performance and growth outlook drive investor confidence, leading to a revaluation of other CGM stocks like Abbott Laboratories (ABT) and Medtronic (MDT). The positive sentiment also impacts the broader healthcare sector, with ETFs like the Health Care Select Sector SPDR Fund (XLV) benefiting.

What to watch next: Investors should monitor DexCom's Q2 2023 earnings, scheduled for August 1, 2023, to confirm its growth trajectory. Additionally, they should keep an eye on the FDA's approval process for DexCom's G8 system, expected in late 2023, which could drive further growth. Lastly, the launch and adoption of DexCom's G7 system in Europe, slated for mid-2023, will indicate international growth potential.